title: Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants.
abstract: The development of new orally administered anticoagulants, such as dabigatran, rivaroxaban, and apixaban, in the past few years has focused on avoiding some of the drawbacks associated with warfarin. This work aims to illustrate the main features of the most commonly used new oral anticoagulants, reviewing the current literature on the management of patients taking these drugs and needing oral and implant surgery, and discussing the currently proposed related guidelines.
authors: Department of Neurosciences, Institute of Clinical Dentistry, University of Padova, Via Venezia 90, 35129, Padua, Italy.
authors: Stefano
authors: S
authors: Sivolella
authors: Department of Neurosciences, Institute of Clinical Dentistry, University of Padova, Via Venezia 90, 35129, Padua, Italy. marleen.debiagi@gmail.com.|DDS, Resident, Institute of Clinical Dentistry, Azienda Ospedaliera, University of Padova, Via Venezia 90, 35129, Padua, Italy. marleen.debiagi@gmail.com.
authors: Marleen
authors: M
authors: De Biagi
authors: Department of Neurosciences, Institute of Clinical Dentistry, University of Padova, Via Venezia 90, 35129, Padua, Italy.
authors: Giulia
authors: G
authors: Brunello
authors: Department of Neurosciences, Institute of Clinical Dentistry, University of Padova, Via Venezia 90, 35129, Padua, Italy.
authors: Mario
authors: M
authors: Berengo
authors: Department of Cardiac Thoracic and Vascular Sciences, Padova University Hospital, Via Giustiniani 2, 35128, Padua, Italy.
authors: Vittorio
authors: V
authors: Pengo
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D000991:Antithrombins / Q000008:administration & dosage* / Q000009:adverse effects; D000069604:Dabigatran / Q000008:administration & dosage / Q000009:adverse effects; D017742:Dental Care for Chronically Ill; D065427:Factor Xa Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D006472:Oral Hemorrhage / Q000139:chemically induced* / Q000517:prevention & control*; D019647:Oral Surgical Procedures; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects; D011728:Pyridones / Q000008:administration & dosage / Q000009:adverse effects; D000069552:Rivaroxaban / Q000008:administration & dosage / Q000009:adverse effects; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D065427:Factor Xa Inhibitors; D011720:Pyrazoles; D011728:Pyridones; C522181:apixaban; D014859:Warfarin; D000069552:Rivaroxaban; D000069604:Dabigatran
keywords: Apixaban; Dabigatran; Oral anticoagulants; Oral surgery; Rivaroxaban
references: Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Apr;113(4):431-41
references: 22668425
references: J Multidiscip Healthc. 2013 Jun 20;6:215-28
references: 23818798
references: J Emerg Med. 2013 Feb;44(2):e221-5
references: 22595629
references: Hematology Am Soc Hematol Educ Program. 2012;2012:536-40
references: 23233631
references: Aust Dent J. 2014 Sep;59(3):296-301; quiz 401
references: 24889878
references: Thromb Haemost. 2012 Nov;108(5):876-86
references: 23014816
references: Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Sep;116(3):e191-5
references: 23850368
references: Clin Pharmacokinet. 2013 Feb;52(2):69-82
references: 23292752
references: Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Dec;116(6):709-16
references: 24120910
references: Blood. 2013 May 2;121(18):3554-62
references: 23476049
references: Blood. 2012 Oct 11;120(15):2954-62
references: 22932800
references: J Postgrad Med. 2012 Oct-Dec;58(4):275-85
references: 23298923
references: Ann Pharmacother. 2012 Apr;46(4):e10
references: 22496474
references: Chest. 2012 Feb;141(2 Suppl):e326S-e350S
references: 22315266
references: Cleve Clin J Med. 2006 Mar;73 Suppl 1:S100-5
references: 16570558
references: Am Heart J. 2012 Jun;163(6):931-937.e1
references: 22709744
references: Thromb Haemost. 2010 Jun;103(6):1116-27
references: 20352166
references: Expert Opin Pharmacother. 2013 Apr;14(5):655-67
references: 23414291
references: Circulation. 2012 Jul 17;126(3):343-8
references: 22700854
references: J Clin Exp Dent. 2014 Apr 01;6(2):e155-61
references: 24790716
references: Intern Emerg Med. 2013 Aug;8(5):371-2
references: 23686690
references: Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 May;113(5):575-80
references: 22668618
references: J Emerg Med. 2013 Sep;45(3):467-77
references: 23786779
references: J Am Soc Nephrol. 2014 Mar;25(3):431-42
references: 24385595
references: Community Dent Oral Epidemiol. 2007 Jun;35(3):215-23
references: 17518968
references: Circulation. 2012 Nov 13;126(20):2428-32
references: 23147769
references: Clin Ther. 2012 Oct;34(10):2051-60
references: 23031622
references: Med Oral Patol Oral Cir Bucal. 2013 May 01;18(3):e461-72
references: 23524440
references: Br J Haematol. 2007 Jan;136(1):26-9
references: 17116128
references: J Can Dent Assoc. 2013;79:d74
references: 23920075
references: Evid Based Dent. 2008;9(1):5-6
references: 18364681
references: Nat Med. 2013 Apr;19(4):446-51
references: 23455714